Drugs / OD-07656
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06206811 | Feb → Nov 2024 | Blau syndrome, Crohn disease, spondyloarthropathy, ulcerative colitis | Odyssey Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06850727 | Jun 2025 → Apr 2026 overdue | ulcerative colitis | Odyssey Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OD-07656 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06850727 ↗ |
| Route | Oral | “administered as an oral capsule” NCT06206811 ↗ |